This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Fudan University. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Xiangyu Qi: Innovator in Pharmaceutical Compounds
Introduction
Xiangyu Qi is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative patent related to heterocyclic amine compounds. His work focuses on addressing various health issues that arise from metabolic abnormalities.
Latest Patents
Xiangyu Qi holds a patent for an "Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof." This patent encompasses alkoxybenzeno five- or six-member heterocyclic amines, their pharmaceutically acceptable salts, and pharmaceutical compositions. These compounds serve as active ingredients in drugs designed to prevent and treat diseases caused by the abnormal increase of SM. Such diseases include atherosclerosis, type II diabetes, fatty liver, obesity, metabolic syndromes, enteritis, and other inflammatory conditions.
Career Highlights
Throughout his career, Xiangyu Qi has worked with esteemed institutions such as Fudan University and Shijiazhuang Yiling Pharmaceutical Co., Ltd. His experience in these organizations has allowed him to develop and refine his innovative ideas in the pharmaceutical sector.
Collaborations
Xiangyu Qi has collaborated with notable colleagues, including Jintong Yang and Jinyu Fei. Their combined expertise has contributed to the advancement of research and development in the field of pharmaceuticals.
Conclusion
Xiangyu Qi's contributions to pharmaceutical innovations highlight his role as a key inventor in addressing critical health challenges. His patent and collaborations reflect a commitment to improving health outcomes through scientific advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
